Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Germany and Serbia weaken Stada's six-month performance

This article was originally published in Scrip

Executive Summary

Stada's domestic sales fell by 8% to €260 million in the first six months of this year, while those in Serbia, the company's seventh largest individual market, fell by 21% to €36 million. The decline was partially offset by the 24% growth of sales to €97 million in Russia, its second most important national market.

You may also be interested in...



COVID-19: Gilead To Fill Remdesivir Supply Gap In EU

As the US firm prepares to ramp up production of the antiviral for use in coronavirus patients, a debate is growing over whether changes could be made to EU rules that prevent the importation of generic drugs produced under a compulsory license.

Pipeline Watch: Phase III Readouts For Daridorexant And Efbemalenograstim

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Executives On The Move: New CEOs At Ipsen, Herantis Pharma And Oncopetides

BeiGene gets a new chief business executive and there are new CMOs at Cellectar Biopharma, MacroGenics and Reata Pharmaceuticals.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1125347

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel